iwNHL 2015 | Approaches to overcome side effects of idelalisib for follicular lymphoma

Name: Approaches to overcome side effects of idelalisib for follicular lymphoma
Uploaded: 2015-10-03T00:00:00.000Z
Duration: 5 min 8 s
Description: At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, John Gribben, MD, DSc, FRCPath, FRCP FMedSci, of Barts and The London School of Medicine and Dentistry, London, UK, discusses the efficacy and safety of idelalisib, a first-in-class selective oral inhibitor of phosphoinositide 3-kinase (PI3K) delta, for the treatment of patients with follicular lymphoma.

John Gribben • 3 Oct 2015

iwNHL 2015

Follicular Lymphoma Non-Hodgkin Lymphoma Idelalisib

At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, John Gribben, MD, DSc, FRCPath, FRCP FMedSci, of Barts and The London School of Medicine and Dentistry, London, UK, discusses the efficacy and safety of idelalisib, a first-in-class selective oral inhibitor of phosphoinositide 3-kinase (PI3K) delta, for the treatment of patients with follicular lymphoma.